🩺What is Intracranial Aneurysm?
The Hunt & Hess classification system was introduced by William E. Hunt and Robert M. Hess in 1968 in an article published in the Journal of Neurosurgery. It was developed to provide a standardized method for grading the surgical risk and prognosis of patients with intracranial aneurysms presenting with subarachnoid hemorrhage. The scale consists of five grades based on clinical severity, ranging from Grade 1 (asymptomatic or minimal symptoms) to Grade 5 (deep coma with decerebrate rigidity). Despite the development of more recent grading systems such as the WFNS (World Federation of Neurological Surgeons) scale, the Hunt & Hess classification remains widely used due to its simplicity and strong correlation with outcomes.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Intracranial Aneurysm:
Hunt & Hess Scale for SAH Grading
The Hunt & Hess Scale is a clinical grading system used to classify the severity of subarachnoid hemorrhage (SAH) based on the patient's neurological status at presentation, providing prognostic information on mortality risk.
🧬Diagnostic Logic & Scoring Breakdown
The Hunt & Hess grade is determined by assessing the patient's clinical neurological status at presentation. Grade 1 requires asymptomatic or minimal headache with slight nuchal rigidity. Grade 2 includes moderate to severe headache with nuchal rigidity and possible cranial nerve palsy but no other neurological deficit. Grade 3 indicates drowsiness, confusion, or mild focal neurological deficit. Grade 4 is stupor with moderate to severe hemiparesis and possible early decerebrate rigidity. Grade 5 is deep coma with decerebrate rigidity and a moribund appearance. Higher grades correlate with increased mortality: Grade 1 (5-10%), Grade 2 (10-15%), Grade 3 (35-40%), Grade 4 (60-70%), Grade 5 (70-90%). The grade should be assessed before sedation or surgical intervention and reassessed after any clinical deterioration.
📢Clinical Significance & Implications
The Hunt & Hess Scale is one of the most widely used clinical grading systems for subarachnoid hemorrhage, recognized by the American Heart Association/American Stroke Association (AHA/ASA) guidelines for SAH management. The scale provides critical prognostic information — mortality increases stepwise from 5-10% in Grade 1 to 70-90% in Grade 5 — and directly influences treatment decisions, including the timing of aneurysm securing, the need for external ventricular drainage, and the intensity of vasospasm monitoring. Grade 1-2 patients are considered "good-grade" SAH with favorable outcomes in 70-80% of cases, while Grade 4-5 patients are "poor-grade" with high rates of morbidity and mortality. The scale also correlates with the risk of vasospasm, delayed cerebral ischemia, and overall functional outcome at discharge and follow-up. Despite the WFNS scale being more recent, Hunt & Hess remains widely used in clinical practice and research. It should be performed at initial presentation and reassessed after any clinical deterioration and before surgical or endovascular intervention.
💡 Clinical Assessment Scenario Example
A 55-year-old woman with a history of hypertension and cigarette smoking presents to the emergency department with the worst headache of her life — a sudden-onset, severe thunderclap headache that began while she was having breakfast. She reports nausea, vomiting, and photophobia. On arrival, she is awake but drowsy, confused about the date and situation, and requires prompting to answer questions. She has mild left-sided arm drift on motor examination (focal neurological deficit). There is significant nuchal rigidity on neck flexion. CT head without contrast reveals diffuse subarachnoid hemorrhage with blood in the basilar cisterns and both sylvian fissures. Hunt & Hess Grade: The patient has drowsiness, confusion, and a mild focal deficit (left arm drift) without stupor or coma. This corresponds to Grade 3. Predicted mortality: 35-40%. Management: The patient is admitted to the neurological ICU. An external ventricular drain is placed for ICP monitoring and CSF drainage given early hydrocephalus. CT angiography reveals a 7 mm anterior communicating artery aneurysm. Nimodipine 60 mg is started via NG tube. The patient undergoes endovascular coiling of the aneurysm on hospital day 1. She develops angiographic vasospasm on day 5 treated with induced hypertension and intra-arterial vasodilators. She is discharged to rehabilitation on day 21 with mild cognitive impairment but no motor deficits.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Intracranial Aneurysm:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Confusing Hunt & Hess with WFNS SAH grading scale
✅ Correction: The Hunt & Hess scale is based on clinical symptoms and signs (headache, nuchal rigidity, level of consciousness, neurological deficit), while the WFNS scale is based specifically on the Glasgow Coma Scale (GCS) and the presence or absence of focal neurological deficit. WFNS Grade 1 = GCS 15 without deficit, Grade 2 = GCS 13-14 without deficit, Grade 3 = GCS 13-14 with deficit, Grade 4 = GCS 7-12, Grade 5 = GCS 3-6. The Hunt & Hess scale offers more detailed clinical descriptors, while WFNS provides more objective and reproducible grading. Both are commonly used in clinical practice and research.
❌ Mistake: Not reassessing Hunt & Hess grade after clinical changes
✅ Correction: The Hunt & Hess grade is dynamic and should be reassessed after clinical deterioration, before aneurysm treatment, and after any major intervention. A patient's grade may improve after ventricular drainage or deteriorate due to rebleeding or vasospasm. The grade at the time of treatment (not just admission) is most predictive of surgical and overall outcomes.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Intracranial Aneurysm; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: What is subarachnoid hemorrhage (SAH)?
Subarachnoid hemorrhage (SAH) is bleeding into the subarachnoid space — the space between the arachnoid mater and the pia mater surrounding the brain. It is most commonly caused by rupture of an intracranial saccular aneurysm (80% of non-traumatic cases). SAH accounts for 5% of all strokes but has a disproportionately high mortality rate of 25-50%. The classic presentation is a sudden, severe thunderclap headache often described as "the worst headache of my life," frequently accompanied by nausea, vomiting, photophobia, nuchal rigidity, and altered consciousness. Non-traumatic SAH is a neurosurgical emergency requiring immediate diagnosis with non-contrast CT head (98% sensitivity within 12 hours) and lumbar puncture if CT is negative. Management focuses on securing the aneurysm (coiling or clipping), preventing rebleeding, managing vasospasm, and treating hydrocephalus.
Q: What is cerebral vasospasm and why is it important?
Cerebral vasospasm is the progressive narrowing of cerebral arteries that occurs 3-14 days after subarachnoid hemorrhage. It is the leading cause of delayed neurological deterioration and death in patients who survive the initial hemorrhage. Vasospasm can lead to delayed cerebral ischemia (DCI) and cerebral infarction if untreated. The pathogenesis involves the breakdown of blood products in the subarachnoid space, particularly oxyhemoglobin, which triggers a cascade of inflammatory and vasoconstrictive responses. Risk factors for vasospasm include poor Hunt & Hess grade, thick cisternal blood on CT, smoking, hypertension, and younger age. Standard prophylaxis includes nimodipine 60 mg PO/NG every 4 hours for 21 days and maintenance of euvolemia. Monitoring is performed using daily transcranial Doppler (TCD) ultrasonography and clinical neurological assessment. Treatment of established vasospasm involves induced hypertension (target SBP 160-200 mmHg), endovascular therapy with intra-arterial vasodilators (verapamil, nicardipine), and/or balloon angioplasty for proximal vessel narrowing.
📚Evidence-Based References
Medically Reviewed By
Dr. Mahmoud El-Sayed, MD, Neurology Specialist
MD | Neurology
Dr. Mahmoud El-Sayed is a neurology consultant with expertise in cerebrovascular disease and TIA management.